Just as Emergent BioSolutions looked to be making some headway in course corrections following a production mishap that ruined millions of doses of Johnson & Johnson’s COVID-19 vaccine, new information indicates the Maryland-based company sought to hide the deficiencies from federal regulators, all while touting its manufacturing capabilities, according to a BioSpace article.
Emergent BioSolutions came into 2022 after a challenging year that saw the company lose a lucrative contract with the U.S. government following a production mishap that ruined millions of doses of Johnson & Johnson’s COVID-19 vaccine.
The U.S. government canceled a contract with Maryland-based Emergent BioSolutions, which ruined about 15 million doses of the Johnson & Johnson vaccine earlier in the year.
Emergent BioSolutions signed a five-year agreement with Providence Therapeutics to develop and manufacture the Canadian biotechnology company’s Covid-19 vaccine candidate for about $90 million.
Following a manufacturing mistake that left Emergent BioSolutions with a botched batch of Johnson & Johnson’s Covid-19 vaccine, the company is facing a shareholder lawsuit accusing it of insider trading.
The U.S. Food and Drug Administration authorized the use of an additional batch of Johnson & Johnson’s one-dose Covid-19 vaccine manufactured at the problem-plagued Baltimore factory of Emergent BioSolutions Inc.
The U.S. Food and Drug Administration said Johnson & Johnson must throw away millions of doses of the company’s Covid-19 vaccine that were manufactured at a problem-plagued Baltimore factory, but also cleared millions for use.
After months of bad news regarding Covid-19 vaccine manufacturing issues, Emergent BioSolutions posted positive two-year data related to the company’s investigational chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate.